Skip to main content
Article thumbnail
Location of Repository

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

By Andrew Thomson
Topics: Clinical Impact Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3321661
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). A prospective, comparative study of the onset of symptomatic benefit of dutasteride versus finasteride in men with benign prostatic hyperplasia in everyday clinical practice. Eur Urol Suppl.
    2. (2003). Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol.
    3. (2004). AUA guidelines and their impact on the management of BPH: an update. Rev Urol.
    4. Benign prostatic hyperplasia specific health measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?
    5. (1995). Benign prostatic hyperplasia: medical and minimally invasive treatment options.
    6. (2002). Benign prostatic hyperplasia: where do we stand in the new millennium. Curr Opin Urol.
    7. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.
    8. Correspondence: Andrew Thomson, Core Medical Publishing, Mere House,
    9. density, bone metabolism markers and lipid profiles in healthy men are unaffected by the novel dual 5α-reductase inhibitor dutasteride.
    10. Dutasteride provides sustained and continued improvement in BPH-related symptoms over 4 years. J Urol.
    11. (2002). Dutasteride, a novel dual 5α-reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients.
    12. (2004). Earlier initiation of treatment with the dual 5α reductase inhibitor dutasteride reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic hyperplasia. Eur Urol Suppl.
    13. Early use of dutasteride arrests prostate growth, improves clinical parameters and prevents complications in men with benign prostatic hyperplasia.
    14. Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment.
    15. Effect of maximal dihydrotestosterone suppression with dutasteride on sexual function and gynecomastia.
    16. (2002). Effect of the dual 5 alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume. Eur Urol Suppl.
    17. Effect of the dual 5α-reductase inhibitor dutasteride on endocrine parameters.
    18. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
    19. (2004). Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology.
    20. (2004). Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol.
    21. Efficacy of dutasteride and finasteride for the treatment of benign prostate hyperplasia: results of the 1-year Enlarged
    22. (2003). Eur Urol Suppl.
    23. Guideline on the management of benign prostatic hyperplasia (BPH).
    24. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor.
    25. (2004). Long-term dutasteride therapy results in sustained reductions in total prostate volume in men with symptomatic benign prostatic hyperplasia. Eur Urol Suppl.
    26. Long-term risk of retreatment of patients using alpha-blockers for lower urinary tract symptoms.
    27. (2002). Managing benign prostatic hyperplasia. Am Fam Phys.
    28. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor.
    29. (2002). Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. Curr Opin Urol.
    30. (2003). Potent DHT suppression by the novel dual 5α-reductase inhibitor dutasteride does not affect bone density, bone metabolism or lipid profiles in healthy men. Eur Urol Suppl.
    31. (2003). Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol.
    32. (1998). The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia.
    33. (2001). The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol.
    34. (2003). The impact of dutasteride, a novel dual 5a-reductase inhibitor, on both serum and intraprostatic androgens. Eur Urol Suppl.
    35. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    36. (1998). The management of men with acute urinary retention.
    37. (2003). The novel dual 5α-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30≤40 cc and 40 cc. Eur Urol Suppl.
    38. The utility of serial PSA measurements for the diagnosis of prostate cancer is preserved in men treated with the dual 5-alpha reductase inhibitor dutasteride.
    39. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial.
    40. (1997). Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharm Exp Ther.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.